Belzutifan (NCT04924075)

Name: Belzutifan trial for Pheochromocytoma/Paraganglioma (NCT04924075)
Uploaded: 2026-10-31T15:55:32.999Z
Duration: 1 min 29 s
Description: Belzutifan trial for Pheochromocytoma/Paraganglioma (NCT04924075). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04924075.

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015): a one-minute explainerNCT049240751 min

Belzutifan trial for Pheochromocytoma/Paraganglioma (NCT04924075). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for people aged 12 or older with advanced pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, wild-type GIST or solid tumors with HIF-2α-related genetic changes. A separate group accepts adults with localized VHL-associated tumors.

The idea: belzutifan blocks HIF-2α, a regulator of genes involved in cancer-cell growth and survival. Participants take 120 mg orally each day until progression or discontinuation. Researchers assess tumor response and safety.

This phase 2 study plans 355 patients. Merck Sharp & Dohme sponsors it, with ten recruiting US sites. Patients must be able to swallow the medication.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.